Skip to main content

HomeResearchDihexa

Educational research tools — not medical advice.

CategoryCognitive
SafetyMedium Risk
RegulatoryNot Evaluated
StatusResearch Only

Dihexa

PNB-0408

CategoryCognitive
Half-lifeUnknown (likely days based on effects)
Routeoral, transdermal, subcutaneous
RiskMedium Risk
Providers46 listed#3 in Cognitive

In brief

Dihexa is a synthetic small peptide drug candidate developed at Washington State University, proposed to augment cognitive function through potentiation of hepatocyte growth factor (HGF) and MET receptor signaling, a…

Medium Risk46 providers listed

About Dihexa

HGF/MET receptor potentiator; promotes new synapse formation; estimated 7 orders of magnitude more potent than BDNF in synaptogenesis models

Dihexa is a synthetic small peptide drug candidate developed at Washington State University, proposed to augment cognitive function through potentiation of hepatocyte growth factor (HGF) and MET receptor signaling, a pathway that supports synaptic formation and hippocampal neuroplasticity. The underlying AT4/IRAP receptor system, through which dihexa is proposed to act, has been shown in preclinical rodent studies to enhance long-term potentiation (LTP) in hippocampal tissue and support neuroplastic processes associated with memory formation. Preclinical models have demonstrated memory-enhancing effects following dihexa administration; however, no peer-reviewed human clinical trials have been published as of 2025 and the compound does not appear in indexed biomedical literature under its common name. Dihexa is a research compound with no regulatory approval of any kind; it is not an approved pharmaceutical, and no human safety or pharmacokinetic data has been established. Dihexa administration in research contexts: the compound has been studied in rodent models via oral, intranasal, and subcutaneous routes, with preclinical data suggesting intranasal delivery may offer efficient CNS access due to olfactory pathway absorption. Nasal spray formulations are available through some research compound suppliers on this basis, though the clinical translatability of rodent CNS delivery data to humans has not been established. Dihexa is structurally derived from angiotensin IV and shares the AT4/IRAP receptor pharmacology of its precursor compounds; it is sometimes compared to semax and other nootropic peptides in terms of proposed cognitive mechanism, though its HGF/MET-dependent mechanism is distinct from the ACTH-fragment or NGF-upregulating mechanisms of semax and selank. The cognitive enhancement peptide landscape — and provider availability for researched compounds in this space — is covered in the PeptideBase cognitive peptides directory.

Dihexa Benefits & Research Areas

HGF/MET receptor potentiation supporting synaptogenesishippocampal LTP enhancement in preclinical modelsmemory and neuroplasticity support (rodent data)no established human safety or pharmacokinetic profile

Research Signals

Population research notes

40s50+

These signals reflect research interest areas, not treatment indications.

Regulatory & Evidence

Risk Profile

Medium Risk

Moderate risk profile in research contexts. Review contraindications and administration guidelines before use.

Regulatory Status

Availability Status
Research Only
FDA Status
Not Evaluated

Angiotensin IV-derived hexapeptide (PNB-0408) from WSU research. Cognitive enhancement in animal models. No FDA approval, no NDA or IND. Not on any FDA list. Research compound only.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Research Sources

2 sources cited · 2 moderate

1 Review · 1 Animal

  • Neural plasticity and the brain renin-angiotensin system

    Neuroscience and Biobehavioral Reviews · 2002

    This review summarizes evidence that angiotensin IV facilitates synaptic remodeling, long-term potentiation, and associative and spatial memory through interactions with the extracellular matrix and AT4/IRAP receptors, while angiotensin II impairs these processes, providing a mechanistic framework for the cognitive-enhancing properties attributed to angiotensin IV-class peptides including dihexa.

    ReviewModeratePMID 12367589
  • Angiotensin IV enhances LTP in rat dentate gyrus in vivo

    Peptides · 2001

    Research in rat hippocampal preparations found that angiotensin IV (the peptide class on which dihexa is based) dose-dependently enhanced long-term potentiation in dentate granule cell synapses, with the effect blocked by the Ang IV antagonist Divalinal, identifying AT4/IRAP receptor activation as a mechanism for angiotensin IV-class facilitation of synaptic plasticity underlying learning and memory.

    AnimalModeratePMID 11514021

Dihexa Side Effects & Safety Considerations

Medium Risk

Moderate risk profile. Review all reported considerations carefully before use.

Reported contraindications & considerations

Active CancerPregnancyUnknown Long-Term Safety

Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.

Research Stacks

Browse all →

Where to Buy Dihexa — Providers & Availability

46 providers
31 Clinics1 Physician46 in stock

Stay updated on verified Dihexa providers

New verified providers added weekly — delivered to your inbox.

Weekly research digest. No spam. Unsubscribe anytime.

Questions to Ask Your Provider

Frequently Asked Questions — Dihexa

Dihexa is a synthetic small peptide drug candidate developed at Washington State University, proposed to augment cognitive function through potentiation of hepatocyte growth factor (HGF) and MET receptor signaling, a pathway that supports synaptic formation and hippocampal neuroplasticity. The underlying AT4/IRAP receptor system, through which dihexa is proposed to act, has been shown in preclinical rodent studies to enhance long-term potentiation (LTP) in hippocampal tissue and support neuroplastic processes associated with memory formation.

HGF/MET receptor potentiation supporting synaptogenesis, hippocampal LTP enhancement in preclinical models, memory and neuroplasticity support (rodent data), no established human safety or pharmacokinetic profile.

Research on Dihexa primarily documents effects related to HGF/MET receptor potentiation supporting synaptogenesis and hippocampal LTP enhancement in preclinical models and memory and neuroplasticity support (rodent data) and no established human safety or pharmacokinetic profile. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

Reported contraindications and considerations for Dihexa include active cancer, pregnancy, unknown long-term safety. This is educational information only — consult a qualified healthcare professional before use.

46 providers in the directory currently offer Dihexa.

This review summarizes evidence that angiotensin IV facilitates synaptic remodeling, long-term potentiation, and associative and spatial memory through interactions with the extracellular matrix and AT4/IRAP receptors, while angiotensin II impairs these processes, providing a mechanistic framework for the cognitive-enhancing properties attributed to angiotensin IV-class peptides including dihexa.

Dihexa is featured in the following research stacks on PeptideBase: Dihexa + Semax: Memory & Cognitive Performance.

Last updated

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.